F. Hoffmann-La Roche AG

Roche, also known as F. Hoffmann-La Roche AG, is a Swiss multinational healthcare company. It operates through two main business divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals division discovers, develops, and produces prescription medicines for areas such as oncology, immunology, infectious diseases, ophthalmology, and neuroscience. The Diagnostics division provides in‑vitro diagnostic tools, including tissue‑based cancer diagnostics, diabetes monitoring, and virology testing, serving hospitals and laboratories worldwide.

The company’s headquarters are located in Basel, Switzerland, where it was founded in 1896. Roche maintains a global presence, with research and development sites, manufacturing facilities, and commercial offices across multiple continents. Its products are distributed to healthcare providers in numerous countries, supporting patient care in both developed and emerging markets. The 2018 Winnti malware incident, in which Roche was targeted as part of a Chinese‑linked espionage campaign, illustrates the company’s exposure to international cyber threats due to its extensive international footprint.

Roche is recognized for its substantial investment in research and development, consistently allocating a significant portion of its revenue to discover new therapeutic agents and diagnostic innovations. The company has pioneered several breakthrough medicines, including monoclonal antibodies such as trastuzumab (Herceptin) and bevacizumab (Avastin), which have become standards of care in oncology. In diagnostics, Roche’s cobas platforms and tissue‑based assays are widely used for clinical decision‑making and personalized medicine approaches. These competencies position Roche as a leading integrated healthcare provider that links drug development with companion diagnostic solutions.

Structurally, Roche Holding AG is the publicly listed parent company traded on the SIX Swiss Exchange under the ticker ROG. While the company has a dispersed shareholder base, the founding Hoffmann and Oeri families retain a substantial ownership interest, influencing long‑term strategic direction. Roche does not operate as a subsidiary of another corporation; instead, it wholly owns numerous subsidiaries that manage its regional operations, research units, and specialized business functions. This governance structure enables Roche to maintain operational independence while pursuing its mission to advance healthcare through science and technology.